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Copyright © 2011 JCBN 2011 This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unre- stricted use, distribution, and reproduction in any medium, pro- vided the original work is properly cited. Resveratrol, a phytoalexin present in the skin of grapes and red
wine, has been demonstrated to possess a wide range of health
promoting activities including anti diabetic properties. In the
present study, we investigated the effect of resveratrol in both
type 2 diabetic mice and cell culture systems. In cultured L6
myotubes, we studied the effect of resveratrol on glucose uptake
and translocation of glucose transporter 4 to plasma membrane
from the aspects of insulin signaling and AMP activated protein
kinase signaling. In cultured RIN 5F cells, we examined whether
resveratrol would protect the pancreas derived β cells from
oxidative stress. Resveratrol significantly suppressed the elevation
in the fasting blood glucose level and the serum triglyceride and
lipid peroxide levels in db/db mice. Resveratrol stimulated glucose
uptake and glucose transporter 4 translocation by activating both
insulin signaling and AMP activated protein kinase signaling.
Moreover, resveratrol could protect pancreatic β cells from
advanced glycation end products induced oxidative stress and
apoptosis. From these results, resveratrol is suggested to show
anti diabetic effect by stimulating both insulin dependent and
 independent glucose uptake in muscles and by protecting
pancreatic β cells from advanced glycation end products induced
oxidative stress and apoptosis.
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Introduction The total number of people with diabetes is increasing
worldwide. To reduce the hyperglycemia, several trials
have been conducted; for instance, inhibition of α-glucosidase
to interfere with glucose absorption from the intestine, stimulation
of pancreatic islet cells to secret insulin, reduction of hepatic
glucose production, and augmentation of glucose utilization.(1,2)
Type 2 (non-insulin-dependent) diabetes is associated with
metabolic syndrome and a marked increase in the risk of cardio-
vascular morbidity and mortality.(3–7) Under diabetic condition,
chronic hyperglycemia and subsequent augmentation of reactive
oxygen species (ROS) increase insulin resistance and deteriorate
β-cell functions which lead to the aggravation of type 2 diabetes.(8)
The skeletal muscles which account for the majority (~80%) of
insulin-mediated glucose uptake in the post-prandial state play
an important role in maintaining glucose homeostasis.(9)
In skeletal muscles, insulin increases glucose uptake via a
signaling that leads to activation of phospatidylinositol-3 kinase
(PI3K) and Akt, resulting in increased translocation of glucose
transporter 4 (GLUT4) to the plasma membrane.(9) Therefore,
skeletal muscle tissue implies an attractive therapeutic target for
the treatment of insulin resistance and type 2 diabetes. There is
another GLUT4 translocation promoter, the AMP-activated
protein kinase (AMPK) which is composed of three subunits, α, β
and γ.(10) In mammalian cells, AMPK activated by an increase in
AMP/ATP ratio acts as an energy sensor,(10) and has at least two
upstream kinases, LKB1 and calmodulin-dependent protein kinase
kinase (CaMKK).(10) AMPK is activated by exercise/contraction(11)
and numerous compounds including metformin(12) and thiazolidine-
dione,(13) resulting in stimulation of glucose uptake in skeletal
muscles. The study of novel compounds that activate AMPK and
increase skeletal muscle glucose uptake could be used for the
development of new treatment of insulin resistance and type 2
diabetes. In the hyperglycemic state, glucose reacts nonenzymati-
cally with protein amino groups to initiate post-translational
modification process known as nonenzymatic glycosylation, or
glycation. This process begins with the conversion of reversible
Schiff base adducts to more stable, covalently bound Amadori
rearrangement products.(14) Over the course of weeks to months,
the Amadori products undergo further rearrangement reactions to
form irreversibly bound moieties called advanced glycation end
products (AGEs).(14,15) Increased oxidative stress and AGEs may
result in the overexpression of receptor of AGEs (RAGE),(16,17)
which is minimally expressed in normal vasculature.(18) The
RAGE gene promoter contains NF-κB binding sites, which posi-
tively control RAGE expression and link RAGE to the inflam-
matory response.(19) Up-regulation of RAGE has been shown to
occur in endothelial cells, smooth muscle cells, and mononuclear
phagocytes in the diabetic vasculature.(20,21) The binding of AGEs
to RAGE activates multiple signaling cascades, including extra-
cellular signal-regulated kinase (ERK) and mitogen-activated
protein kinase (MAPK), and the generation of ROS.(22) ROS
augmentation reportedly deteriorates β-cell functions, because
gene expression of antioxidant enzymes such as glutathione
peroxidase and catalase was very low in pancreatic cells.(23,24)
Thus, β-cells are vulnerable to oxidative stress, leading to the
reduction of insulin secretion.
Resveratrol (3,5,4'-trans-trihydroxystilbene), a phytoalexin poly-
phenol that is found naturally in such as grapes, peanuts and
mulberries. Resveratrol has a number of health benefits including
anticarcinogenic,(25) cardiovascular protective(26) and estrogenic
activities(27) as well as anti-inflammatory,(28) free-radical scav-
enging(29) activities, inhibition/induction of apoptosis,(30) inhibition
of platelet aggregation,(31) life-extension,(32) and neuroprotection.(33)
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We have reported that resveratrol shows anti-invasive effect against
hepatoma cells,(34–36) and hypolipidemic effect in glomerulone-
phritic(37) and hepatoma-bearing rats.(38)
Although a number of studies concerning the effect of resveratrol
on diabetes or hyperglycemia have been reported, little has been
validated in type 2 diabetes model animals. Hence, the present
study is intended to investigate comprehensive effect of resveratrol
on metabolic functions in type 2 diabetic model animals (db/db
mice) as well as myotubes and pancreatic β-cells in culture. The
db/db mice are characterized by obesity, insulin resistance, severe
hyperglycemia, pancreatic injury and cardiovascular complica-
tions, and therefore regarded as a useful model of heavy human
type 2 diabetes.(39,40)
Materials and Methods
Materials. L6 myoblasts derived from a rat(41) and RIN-5F
cells derived from rat pancreatic β-cells(42) were purchased from
American Type Culture Collection (Manassas, VA; ATCC®
numbers: CRL-1458 and CRL-2058, respectively), Dulbecco’s
modified Eagle medium (DMEM) and RPMI 1640 medium were
from Nissui Pharmaceutical Co., (Tokyo, Japan), fetal bovine
serum (FBS) was from JRH Biosciences, (Lenexa, KS) and
streptomycin and penicillin G were from Nacalai Tesque, Inc.,
(Kyoto, Japan). Resveratrol, bovine serum albumin (BSA, fatty
acid free) and Triton X-100 were purchased from Sigma Chemical
Co., (St. Louis, MO). Glucose, total cholesterol (T-Ch) and
triglyceride (TG) assay kits (Glucose CII Test Wako, Cholesterol
E-Test Wako and Triglyceride E-Test Wako, respectively) were
from Wako Pure Chemical Industries, Ltd., (Osaka, Japan). Serum
lipid peroxide was estimated as thiobarbituric acid-reactive
substances (TBARS) with a commercial kit (TBARS Assay Kit,
ZeptoMetrix Corporation, Buffalo, NY). Insulin assay kit was
from Morinaga Institute of Biological Science, Inc., (Yokohama,
Japan). The anti-phospho-Akt (Ser473) antibody was obtained
from Upstate Biotechnology (Lake Placid, NY). The anti-Akt1
antibody was obtained from Santa Cruz Biotechnology (Santa
Cruz, CA). The anti-phospho-AMPKα (Thr172) and anti-AMPK
antibodies were obtained from Cell Signaling Technology, Inc.,
(Beverly, MA). Anti-Na+/K+ ATPase α-1 antibody from Millipore
(Billerica, MA), anti-GLUT4 antibody from AbD Serotec (Oxford,
UK), horseradish peroxidase-conjugated anti-mouse and anti-
rabbit IgG antibodies from Invitrogen (San Diego, CA). All other
chemicals were of the best grade commercially available, unless
otherwise noted. Plastic multiwell plates and tubes were obtained
from Nunc A/S (Roskilde, Denmark) or Iwaki brand (Asahi Glass
Co., Ltd., Tokyo, Japan).
Effect of resveratrol on blood glucose levels in db/db
mice. All animal experiments were conducted in accordance
with guidelines established by the Animal Care and Use
Committee of Tokyo University of Agriculture and Technology
and were approved by this committee. To determine the effect of
resveratrol on fasting blood glucose levels, db/db mice were used
as a model of type 2 diabetes. Male db/db and its misty (m/m)
control (normal) mice (5 weeks of age) were obtained from
Charles River Japan, Kanagawa, Japan. Animals were individually
housed in stainless-steel cages with wire bottoms in an air-
conditioned room with a temperature of 22 ± 2°C, a relative
humidity of 60 ± 5%, and an 8:00–20:00 light cycle. All mice
were maintained on a stock CE-2 pellet diet (CLEA Japan, Tokyo,
Japan) for 3 days and thereafter a basal 20% casein diet (20C)
for 4 days. The composition of the 20C diet was as follows
(dry weight basis): 20% casein (Oriental Yeast Co., Tokyo, Japan),
7% corn oil (Hayashi Chemicals Co., Tokyo, Japan), 13.2% α-
cornstarch (Nihon Nosan Kogyo Co., Yokohama, Japan), 49.75%
β-cornstarch (Nihon Nosan Kogyo Co.), 3.5% mineral mixture
(AIN-93G composition, Nihon Nosan Kogyo Co.), 1% vitamin
mixture (AIN-93 composition, Nihon Nosan Kogyo Co.), 0.25%
choline bitartrate (Wako Pure Chemical Industries), 0.3% L-
cystine (Wako Pure Chemical Industries), and 5% cellulose
powder (Oriental Yeast Co.). After preliminary feeding for 1
week, mice were deprived of their diet at 9:00 a.m. but allowed
free access to water until blood collection from tail vein 4 h
later. Blood (10 μl) was burst in water (40 μl), 20% (w/v)
trichloroacetic acid aqueous solution (50 μl) was added and test
tubes containing the mixture were kept in ice-cold water. The
mixture was then centrifuged at 13,000 × g and 4°C for 5 min. The
resultant supernatant (80 μl) was subjected to glucose determina-
tion with a commercial kit and a spectrophotometer (Model U-1100,
Hitachi Science Systems, Ltd., Ibaraki, Japan) at 505 nm,(43) and
db/db mice (6 weeks of age at the moment) were divided into two
groups of similar fasting blood glucose levels and body weights
(0 week). Diabetic mice of each of the two groups were given
either the 20C as the control group or the 20C supplemented with
0.04% resveratrol as the test group for 5 weeks. Resveratrol was
supplemented to the 20C at the expense of β-cornstarch. Likewise,
misty control mice were given the 20C as the normal group for
5 weeks.
Syntheses of advanced glycation end products (AGEs).
AGEs were generated from co-incubation of BSA with either
D-glucose (AGE1) or D-glyceraldhyde (AGE2) according to the
method of Kume et al.(44) AGE1 and AGE2 were incubated at
37°C for 8 weeks and 2 weeks, respectively. BSA alone was
incubated at 37°C for 2 weeks under conditions without any
carbohydrates, and employed as the control for AGE1 and AGE2.
This BSA was designated as CNT.
Determination of glucose uptake by cultured L6 myo 
tubes. Stock cultures of L6 myoblasts were maintained in
DMEM supplemented with 10% (v/v) FBS, streptomycin (100 μg/
ml), and penicillin G (100 U/ml) (10% FBS/DMEM) under an at-
mosphere of 5% CO2/95% humidified air at 37°C as described
previously.(45) Effect of resveratrol was examined by the procedure
described previously(43,46) with slight modifications. Briefly, the L6
myoblasts (5 × 104 cells/well) were subcultured into Nunc 24-place
multiwell plates and grown for 11 days to form myotubes in 0.4 ml
of 10% FBS/DMEM. The medium was renewed every 3 days.
Later, the 11-day-old myotubes were kept for 2 h in filter-steril-
ized Krebs-Henseleit buffer (pH 7.4, 141 mg/l MgSO4, 160 mg/l
KH2PO4, 350 mg/l KCl, 6900 mg/l NaCl, 373 mg/l CaCl2-2H2O
and 2100 mg/l NaHCO3) containing 0.1% bovine serum albumin,
10 mM Hepes and 2 mM sodium pyruvate (KHH buffer). The
myotubes were thereafter cultured in KHH buffer containing
11 mM glucose without or with resveratrol (1–100 μM) for
another 4 h. Glucose concentrations in KHH buffer were deter-
mined with a glucose assay kit and a microplate reader (Appliskan,
Thermo Fisher Scientific Inc., MA) at 508 nm, and the amounts of
glucose consumed were calculated from the differences in glucose
concentrations between before and after culture.
Preparation of plasma membrane from L6 myotubes.
The L6 myoblasts (5 × 105 cells) were subcultured into Nunc
60 mm dishes and grown for 11 days to form myotubes in 3 ml of
10% FBS/DMEM. The medium was renewed every 3 days. Later,
the 11-day-old myotubes were kept for 2 h in KHH buffer. Then,
the myotubes were cultured in KHH buffer containing 11 mM
glucose without or with resveratrol (10, 100 μM) for appropriate
time intervals. Then, plasma membrane fractions were obtained
by the method described by Nishiumi and Ashida.(47) Briefly, to
prepare the plasma membrane and post-plasma membrane fraction,
L6 myotubes were harvested with buffer A (50 mM Tris-HCl
(pH 8.0), 0.5 mM DTT, protease inhibitor cocktail and 1 mM
Na3VO4 (Nacalai Tesque, Inc., Kyoto, Japan) containing 0.1%
(v/v) IGEPAL CA-630 (Sigma Chemical Co.), and homogenated
with 21-gauge needle. Each homogenate was centrifuged at
1,000 × g for 10 min at 4°C, and the precipitate was suspended
in IGEPAL CA-630-free buffer A, and recentrifuged at 1,000 × g
for 10 min at 4°C. The precipitate obtained was suspended again J. Clin. Biochem. Nutr. | May 2011 | vol. 48 | no. 3 | 239
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in buffer A containing 1.0% (v/v) IGEPAL CA-630, stood on
ice for 1 h with occasional mixing and centrifuged at 16,000 × g
for 20 min at 4°C. The supernatant was collected and stored as
the plasma membrane fraction at −80°C until analyses. The
supernatant from the first 1,000 × g centrifugation was gathered
and centrifuged again at 16,000 × g for 20 min at 4°C. The
supernatant obtained was collected and used as a post-plasma
membrane fraction.
Preparation of cell lysate. The 11-day-old myotubes were
kept for 2 h in KHH buffer. Then, the myotubes were cultured in
KHH buffer containing 11 mM glucose with resveratrol (10 μM)
for appropriate time intervals. The cells were scraped from the
plates into ice-cold RIPA lysis buffer (Nacalai Tesque) and
centrifuged for 20 min at 4°C and 16,000 × g. The supernatant
was collected and stored at −80°C until use.
Western blotting. Protein samples were separated by SDS–
PAGE, transferred to a PVDF membrane which was blocked for
1 h with 5% (w/v) dry milk in Tris-buffered saline, and incubated
overnight at 4°C with the primary antibody. The primary antibody
was detected with HRP-conjugated anti-rabbit or anti-mouse
secondary antibody and visualized by using the SuperSignal West
Pico Chemiluminescent Substrate (Thermo Fischer, Rockford, IL).
Measurement of intracellular ROS. RIN-5F cells derived
from rat pancreatic β-cells were maintained in RPMI 1640 supple-
mented with 10% (v/v) FBS, streptomycin (100 μg/ml), and
penicillin G (100 U/ml) (10% FBS/RPMI 1640) under an
atmosphere of 5% CO2/95% humidified air at 37°C. The medium
was renewed every 3 days. The cells (5 × 105 cells/well) were
cultured into Nunc 12-place multiwell plates. After being cultured
for 72 h in 1 ml of 10% FBS/RPMI 1640, the medium in each
well was removed. Thereafter, RIN-5F cells received 1 ml of
fresh medium (1% FBS/RPMI 1640) without or with resveratrol
and AGEs for another 3 h. Effect of resveratrol on oxidative stress
was examined by measurement of intracellular ROS based on
ROS-mediated conversion of non-fluorescent 2',7'-DCFH-DA
into DCFH.(48) The intensity of fluorescence reflects enhanced
oxidative stress. After the 3 h incubation, RIN-5F cells were
incubated with DCFH-DA (final 25 μM) in 1% FBS/RPMI 1640
at 37°C for 20 min. At the end of the incubation, DCFH fluores-
cence of the cells from each well was measured at an emission
wavelength of 530 nm and an excitation wavelength of 488 nm
using a flow cytometer (Becton Dickinson, San Jose, CA).
Flow cytometric evaluation of apoptosis. RIN-5F cells
received 1 ml of fresh medium (1% FBS/RPMI 1640) containing
200 μg BSA alone (CNT) or AGE2 without or with 50 μM
resveratrol for another 6 h. Effect of resveratrol on oxidative
stress-induced apoptosis was examined by using an Annexin
V-FITC apoptosis detection kit (Becton Dickinson, San Jose, CA).
Annexin V has a strong, Ca2+-dependent affinity for phosphatidyl-
serine (PS), which translocates from the internal to the external
surface of the plasma membrane as a probe for detecting apop-
tosis.(49) Samples were incubated on ice for 10 min in the dark with
Annexin V and propidium iodide (PI) and analyzed with a flow
cytometer.
Statistical analysis. Data are expressed as means ± standard
errors of means (SEM). Multigroup comparisons were carried
out by one-way analysis of variance (ANOVA) followed by
Tukey-Kramer multiple comparisons test (Instat ver 2.00,
GraphPad Software Inc., San Diego, CA). Values of p < 0.05 were
considered statistically significant.
Results
Effect of resveratrol on blood glucose level and other
parameters in db/db mice. To study the in vivo effect of
resveratrol, we employed db/db mice, a model for type 2 diabetes.
Fig. 1A shows the effect of resveratrol on the fasting blood
glucose level. The blood glucose level linearly increased to the
third week of feeding and thereafter maintained the high value up
to fifth week in diabetic control mice, while it was unchanged
and constant in normal mice for this period. Resveratrol (0.04%
in diet) tended to suppress until the second week of feeding and
significantly suppressed the rise in the blood glucose level at the
third week and thereafter. As shown in Fig. 1B, food intake of the
resveratrol group for 5 weeks was almost the same as that of the
control group, suggesting that the suppressive effect of resveratrol
on fasting blood glucose level was not due to reduced food intake
but due to its pharmacological action. As seen in Fig. 1C, T-Ch,
TG and TBARS concentrations in serum of the diabetic control
group significantly increased as compared with those of the
normal group. Resveratrol, however, significantly suppressed the
rises in the TG and TBARS concentrations. Serum insulin concen-
tration in the control group tended to increase as compared with
that in the normal group. The concentration in the resveratrol
group also tended to increase as compared with that in the control
group. However, these differences in insulin concentrations
between the normal and diabetic control groups and between
the diabetic control and resveratrol groups were not statistically
significant (Fig. 1C).
Resveratrol accelerated glucose uptake ability and effec 
tively translocated GLUT4 to plasma membrane. To investi-
gate mechanisms for resveratrol actions in vivo, we first examined
its effect on glucose uptake by L6 myotubes in vitro (Fig. 2).
Resveratrol dose-dependently increased glucose uptake at concen-
trations of 1–100 μM in the absence of insulin.
Myotubes take glucose by mainly using GLUT4. Its recruitment
to the surface of muscle cells is induced by both insulin and
exercise.(50,51) Thus, we examined whether or not resveratrol would
promote GLUT4 translocation to plasma membrane by western
blotting analyses using antibodies to GLUT4 and Na+/K+ ATPase,
the latter being a plasma membrane marker enzyme. Treatment of
L6 myotubes with 100 μM resveratrol for 15 min promoted
GLUT4 translocation (Fig. 3A). Phosphorylation ratios of AMPK
and Akt commenced to increase 15 min after resveratrol (10 μM)
treatment and thereafter further increased up to 240 min (Fig. 3 B
and C). Time-dependent changes of GLUT4 translocation after
resveratrol treatment are shown in Fig. 3 D and E. While maximum
translocation of GLUT4 was attained 5–10 min after treatment
and thereafter GLUT4 gradually diminished at the low concentra-
tion of resveratrol (10 μM), GLUT4 rapidly translocated to plasma
membrane 2.5 min after treatment and maintained the promotive
effect up to 40 min at the high concentration of resveratrol
(100 μM).
Resveratrol protects pancreatic β cells from oxidative
stress. As above-mentioned, β-cells are vulnerable to oxidative
stress. Resveratrol is one of polyphenols with antioxidative
property. Thus, the effect of resveratrol on the AGEs-induced
oxidative stress was investigated in RIN-5F cells. RIN-5F cells
that had been adhered and pre-cultured with medium alone for
72 h were treated with resveratrol or medium alone for another
3 h. At the end of the culture, the intracellular peroxide level was
measured with DCFH-DA fluorescent probe. The fluorescence
intensity of the resveratrol-treated group was significantly lower
than that of the control (0 μM resveratrol) group (Fig. 4A). This
result suggested that resveratrol might reduce oxidative stress in
RIN-5F cells. To verify this hypothesis, RIN-5F cells were given
oxidative stress by adding AGE1 and AGE2, BSA conjugated
with glucose and glyceraldehyde, respectively, to experimental
media. Control cells were incubated with BSA alone (CNT)
(Fig. 4B). After 3 h treatment with AGEs, fluorescence intensity
of AGE1 and AGE2-treated cells was significantly higher than
that of the CNT-treated cells (Fig. 4 B and E). In the same experi-
ments with AGEs, treatment of RIN-5F cells with resveratrol for
3 h resulted in dramatic reductions in oxidative stress with
significant differences (Fig. 4 C, D and E). These results clearly
defined that resveratrol was capable to protect pancreatic β-cellsdoi: 10.3164/jcbn.10 119
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from AGEs-induced oxidative stress.
Resveratrol protects pancreatic β cells from oxidative
stress induced apoptosis. We examined the effect of resvera-
trol on oxidative stress-induced apoptosis in RIN-5F cells. To
quantitatively gain insight into anti-apoptotic effect of resveratrol
in AGE2-treated RIN-5F cells, a display of propidium iodide (PI)
versus Annexin V-FITC fluorescence was measured by flow
cytometric analysis (Fig. 5). Annexin V-positive and PI-negative
cells, which are shown in quadrant E4 in Fig. 5 A and B, are
thought to be early apoptotic cells.(52) RIN-5F cells were exposed
to 200 μg/ml CNT and AGE2 in the absence or presence of 50 μM
resveratrol for 6 h (Fig. 5 A and B). In this experiment, AGE2 was
selected, because it induced more notable oxidative stress in
RIN-5F cells than did AGE1 (Fig. 4E). The percentage of apop-
tosis in AGE2-treated cells was significantly higher than that in
CNT-treated cells (Fig. 5C). In the same experiments with CNT
and AGE2, treatment of RIN-5F cells with resveratrol for 6 h
resulted in significant reductions in the percentage of apoptosis
(Fig. 5C).
Discussion
Many kinds of phytochemicals have been reported to possess
anti-diabetic potentials.(43,53,54) Resveratrol has been reported to
competent to shift the physiology of mice on a high-calorie diet
towards that of mice on a standard diet and improves their survival
and insulin sensitivity.(32) This polyphenol also has been found to
possess an insulin-mimetic effect in type 1 diabetic model rats and
to ameliorate several metabolic parameters.(55) In the present study,
resveratrol was demonstrated to suppress the elevation in the
blood glucose level and partially improved dyslipidemia in type 2
Fig. 1. Effect of resveratrol on blood glucose level and other parameters in db/db mice. A: Effect of resveratrol on the fasting blood glucose level.
Mice were fasted for 4 h before blood collection. B: Food intake per mouse for 5 weeks. C: Serum levels of T Ch, TG, TBARS and insulin were
determined at fifth week of feeding. NOR, CNT and RES indicate normal, diabetic control and resveratrol treated groups, respectively. Each value
represents the mean ± SEM for 5 (NOR, RES,) and 4 (CNT) mice. Values not sharing a common letter are significantly different at p < 0.05 by Tukey 
Kramer multiple comparisons test.
Fig. 2. Effect of resveratrol on glucose uptake in cultured L6 myotubes.
Each value represents the mean ± SEM for 6 wells. Values not sharing a
common letter are significantly different at p < 0.05 by Tukey Kramer
multiple comparisons test. J. Clin. Biochem. Nutr. | May 2011 | vol. 48 | no. 3 | 241
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diabetic model db/db mice. Serum lipid peroxide (TBARS)
concentration was significantly lower in the resveratrol group than
in the diabetic control group (Fig. 1C). This result suggests that
antioxidative property of resveratrol is available in vivo as well as
in vitro (Fig. 4).
AMPK is an important protein to provide energy in mammalian
cells.(10) Previous reports showed that resveratrol activated AMPK
signaling(32,56) or insulin signaling including Akt.(57) In the present
study, we found for the first time that resveratrol promoted
rapidly endogenous GLUT4 translocation through simultaneously
enhancing phosphorylation of both AMPK (AMPK signaling) and
Akt (insulin signaling), resulting in stimulation of glucose uptake
in skeletal muscle cells. Although AMPK signaling is independent
of insulin signaling, GLUT4 translocation to plasma membrane is
a common final event. Thus, resveratrol is suggested to effectively
improve and overcome insulin resistance.
Activation of rennin-angiotensin-aldosterone system has been
reported to increase ROS and impaired insulin signaling. Trans-
genic Ren2 rats manifest increased tissue rennin-angiotensin
system activity, hypertension and insulin resistance.(58) In the
soleus muscle of Ren2 rats, along with increased NADPH oxidase
activity and ROS, there was systemic insulin resistance and
reduced IRS-1 tyrosine phosphorylation, Akt phosphorylation/
activation, and GLUT4 expression,(58) suggesting oxidative stress
disturbs insulin signaling in muscle tissues. In isolated cardio-
myocytes, elevated levels of lipid peroxidation product 4-hydroxy-
2-nonenal (HNE) have been reported to result in the formation
of HNE-LKB1 adducts that inhibit LKB1 and hence AMPK
activity.(59) Treatment of cardiomyocytes with resveratrol prevents
HNE modification of the LKB1/AMPK signaling.(59) If this be
true of L6 myotubes and skeletal muscle tissues of db/db mice,
oxidative stress is also suggested to disturb AMPK signaling in
muscle tissues and to be improved by resveratrol treatment. These
two findings are not inconsistent with the results shown in Fig. 3.
In the diabetic state, glycation reaction is observed in various
tissues and organs, and various kinds of glycated proteins such as
glycosylated hemoglobin, albumin, and lens crystalline are pro-
duced in a nonenzymatical manner through the glycation reaction.
The reaction produces Schiff base, Amadori product, and finally
AGEs.(8) In the present study, the resveratrol group was still in the
high blood glucose state in db/db mice, although the polyphenol
lowered the level of blood glucose significantly as compared with
that of the diabetic control group. Therefore, syntheses of AGEs
might occur in both the control and resveratrol groups. Non-
etheless, our data demonstrated that resveratrol protected RIN-5F
cells from AGEs-induced oxidative stress (Fig. 4) and AGEs-
induced apoptosis (Fig. 5), which is followed by decreasing
insulin gene expression and secretion. Although not statistically
Fig. 3. Effect of resveratrol on translocation of GLUT4 to plasma membrane and phosphorylation of AMPK and Akt. A: Translocation of GLUT4 to
plasma membrane of L6 myotubes which were exposed to 100 μM resveratrol for 15 min. GLUT4 and plasma membrane were detected by western
blotting analyses with anti GLUT4 and anti Na+/K+ ATPase antibodies. Post PM and PM indicate post plasma membrane and plasma membrane
fractions, respectively. B, C: Effect of resveratrol on phosphorylation of AMPK (B) and Akt (C). L6 myotubes were exposed to resveratrol (10 μM) for
indicated time intervals. Western blotting analyses were carried out with anti AMPK, anti phospho AMPK, anti Akt and anti phospho Akt anti 
bodies. D, E: Time dependent changes of GLUT4 translocation in L6 myotubes at 10 μM (D) or 100 μM (E) resveratrol. L6 myotubes were exposed to
resveratrol for indicated time intervals. Plasma membrane fractions of L6 myotubes were subjected to western blotting analyses.doi: 10.3164/jcbn.10 119
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Fig. 4. Effect of resveratrol on AGEs induced oxidative stress in RIN 5F cells. Intracellular ROS in RIN 5F cells were measured with DCFH DA
fluorescent probe and a flow cytometer. A: Effect of resveratrol on basal ROS in RIN 5F cells. B: Effects of AGE1 and AGE2 on intracellular ROS levels
in RIN 5F cells after 3 h treatment with AGEs. BSA alone (CNT) was used as control. C, D: Effect of resveratrol on AGEs induced oxidative stress.
E: Graph of statistically processed data. Each value represents the mean ± SEM for 4 assays. Values not sharing a common letter are significantly
different at p < 0.001 by Tukey Kramer multiple comparisons test.
Fig. 5. Effect of resveratrol on AGE2 induced apoptosis in cultured RIN 5F cells. The cells were exposed to resveratrol and/or AGE2 for 6 h. BSA
alone (CNT) (A) and AGE2 (B) were added to media at a concentration of 200 μg/ml in the absence or presence of 50 μM resveratrol. C: Graph of
statistically processed data. Each value represents the mean ± SEM for 3 assays. Values not sharing a common letter are significantly different at
p < 0.05 by Tukey Kramer multiple comparisons test. J. Clin. Biochem. Nutr. | May 2011 | vol. 48 | no. 3 | 243
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significant, the serum insulin level of the resveratrol group tended
to increase as compared with that of the diabetic control (Fig. 1C),
suggesting that resveratrol might partially rescue exhausted
pancreatic  β-cells of db/db mice from further AGEs-induced
oxidative stress and apoptosis. It is necessary to analyze common
signals in vivo such as levels of AGEs, AMPK phosphorylation
and GLUT4 translocation in the skeletal muscle of db/db mice to
tie the results obtained in vitro in the present study. Further
intensive studies from these aspects are required to clarify the
precise mechanisms for anti-diabetic action of resveratrol. In a
recent study, resveratrol alleviated diabetes mellitus induced
vasculopathy through attenuation of RAGE for AGE-NF-κB
signaling pathway.(60) These previous and present experimental
results raise the possibility that resveratrol has health benefits as
both forceful protector of pancreatic β-cells and soothing agent of
hyperglycemia as well as stimulator of glucose uptake by muscle.
In summary, resveratrol was suggested to suppress the elevation
in the blood glucose level in db/db mice. This polyphenol showed
antioxidative property both in vitro and in vivo. Results obtained
also suggested that resveratrol might enhance glucose uptake in
the muscle via both AMPK and insulin signaling pathways and
reduce the exhaustion of pancreatic β-cells in db/db mice.
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AGEs advanced glycation end products
AMPK AMP-activated protein kinase
BSA bovine serum albumin
CaMKK calmodulin-dependent protein kinase kinase
DMEM Dulbecco’s modified Eagle medium
ERK extracellular signal-regulated kinase 
FBS fetal bovine serum
GLUT4 glucose transporter 4
HNE 4-hydroxy-2-nonenal
IRS-1 insulin receptor substrate-1
LKB1 liver kinase B1
MAPK mitogen-activated protein kinase
NADPH oxidase
nicotinamide adenine dinucleotide phosphate oxidase
PI propidium iodide
PI3K phospatidylinositol-3 kinase
PS phosphatidylserine
RAGE receptor of AGEs
ROS reactive oxygen species
TBARS thiobarbituric acid-reactive substances
T-Ch total cholesterol
TG triglyceride
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